Video

Dr. Abou-Alfa on Key Eligibility Criteria for the PROOF Trial in Cholangiocarcinoma

Ghassan K. Abou-Alfa, MD, discusses key eligibility criteria for the phase 3 PROOF trial in cholangiocarcinoma.

Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses key eligibility criteria for the phase 3 PROOF trial (NCT03773302) in cholangiocarcinoma.

The PROOF study is evaluating oral infigratinib (BGJ398) as first-line treatment for patients with cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or translocations.

The study is ongoing and currently recruiting patients.

Eligible patients have to have a confirmed diagnosis of unresectable locally advanced or metastatic cholangiocarcinoma with a confirmed FGFR2 gene fusion or translocation, says Abou-Alfa. Additionally, patients have to have an available tissue sample for molecular testing, an ECOG performance status of 0 or 1, be able to swallow and retain oral medication, and a willingness to avoid pregnancy or fathering children.

Exclusion criteria include prior systemic therapies, a history of liver transplant, and prior FGFR or MEK inhibitor therapy, among other criteria that could influence outcomes, Abou-Alfa concludes.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Piotr Rutkowski, MD
Yelena Y. Janjigian, MD
Zhi Peng, MD